Endothelial Glycocalyx Biomarkers in Early Cardiovascular Dysfunction

Abstract

The endothelial glycocalyx has emerged as a critical determinant in vascular homeostasis and the early pathogenesis of cardiovascular dysfunction. Recent advances in biomarker research highlight the diagnostic and prognostic utility of glycocalyx degradation products in detecting subclinical endothelial injury. This review synthesizes current evidence regarding the epidemiology, pathophysiology, risk factors, clinical features, diagnosis, management, and guideline-based recommendations for the application of endothelial glycocalyx biomarkers in early cardiovascular dysfunction, with a focus on translational and clinical relevance for healthcare professionals.

Introduction

Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality globally. Early endothelial dysfunction is a pivotal event in the continuum of atherogenesis and heart failure. The endothelial glycocalyx, a carbohydrate-rich layer lining the luminal surface of vascular endothelial cells, functions as a mechanotransducer and selective barrier, regulating vascular permeability, inflammation, and coagulation. Disruption of this structure has been linked to the initiation and progression of cardiovascular pathology. Biomarkers reflecting glycocalyx injury have gained attention as sensitive indicators of early vascular dysfunction, potentially offering opportunities for timely intervention.

Epidemiology / Disease Burden

The global burden of CVDs is projected to increase, with over 17.9 million deaths annually. Subclinical endothelial dysfunction, often underdiagnosed, frequently precedes overt cardiovascular events. Studies reveal that populations with high prevalence of metabolic syndrome, diabetes, hypertension, and chronic kidney disease (CKD) exhibit increased glycocalyx degradation, correlating with heightened cardiovascular risk. Early identification of at-risk individuals through glycocalyx biomarkers may facilitate targeted preventive strategies and reduce disease burden.

Pathophysiology

The endothelial glycocalyx comprises proteoglycans, glycosaminoglycans (such as syndecan-1 and heparan sulfate), and associated plasma proteins. It serves as a physical and biochemical interface between blood and endothelial cells, modulating shear stress, nitric oxide signaling, and leukocyte adhesion. Enzymatic degradation (by heparanase, metalloproteinases) or oxidative stress leads to glycocalyx shedding, resulting in increased vascular permeability, inflammation, and prothrombotic states. Circulating levels of syndecan-1, hyaluronic acid, and other glycocalyx components are elevated in early vascular injury, providing mechanistic insights and measurable indicators of disease activity.

Risk Factors

Risk factors for glycocalyx degradation overlap with traditional cardiovascular risk factors. Hyperglycemia, dyslipidemia, hypertension, smoking, systemic inflammation, and oxidative stress all contribute to glycocalyx damage. Critically ill patients, especially those with sepsis or acute coronary syndromes, exhibit profound glycocalyx injury. Iatrogenic factors, such as hypervolemia or rapid fluid shifts, can exacerbate degradation in perioperative and intensive care settings. Understanding these risk associations underscores the importance of monitoring glycocalyx integrity in high-risk populations.

Clinical Features

Early endothelial dysfunction is clinically silent but precedes the onset of atherosclerosis, microvascular angina, and heart failure with preserved ejection fraction (HFpEF). Loss of glycocalyx integrity manifests as increased vascular permeability, tissue edema, impaired microcirculatory flow, and heightened inflammatory response. In acute scenarios, such as myocardial infarction or sepsis, rapid glycocalyx shedding is associated with worse outcomes. Recognizing these subtle clinical manifestations can aid in the early identification of cardiovascular dysfunction.

Diagnosis

Non-invasive assessment of endothelial function traditionally relies on flow-mediated dilation (FMD) and pulse wave analysis. However, these methods lack specificity for glycocalyx injury. Measurement of circulating glycocalyx components syndecan-1, heparan sulfate, and hyaluronan using ELISA or mass spectrometry offers a direct, quantifiable index of endothelial health. Recent studies demonstrate that elevated syndecan-1 is predictive of adverse cardiac events in patients with acute coronary syndromes and heart failure. Integration of these biomarkers into routine clinical practice may enhance risk stratification and monitoring of therapeutic response.

Treatment & Management

Current management of early cardiovascular dysfunction centers on risk factor modification and pharmacologic interventions targeting endothelial protection. Statins, ACE inhibitors, and antidiabetic agents exert favorable effects on glycocalyx preservation through reduction of oxidative stress and inflammation. Emerging evidence supports the role of antioxidants (e.g., vitamin C, sulodexide) and lifestyle interventions (exercise, glycemic control) in mitigating glycocalyx degradation. Individualized therapy guided by biomarker levels may optimize vascular health and delay progression to overt cardiovascular disease.

Recent Advances / Emerging Therapies

Research into therapeutic restoration of the endothelial glycocalyx is rapidly evolving. Novel agents such as synthetic glycosaminoglycans, recombinant human thrombomodulin, and heparanase inhibitors show promise in preclinical and early-phase clinical trials. Point-of-care assays for glycocalyx biomarkers are under development, enabling rapid bedside assessment. Personalized medicine approaches, leveraging biomarker profiles, may soon allow for tailored interventions aimed at preserving or restoring glycocalyx integrity in high-risk patients.

Guideline Recommendations

While international cardiovascular guidelines recognize the prognostic significance of endothelial dysfunction, formal recommendations for routine assessment of glycocalyx biomarkers are lacking. The European Society of Cardiology and American Heart Association emphasize early detection and management of vascular risk, and ongoing trials may inform future guideline updates. Clinicians should remain vigilant for advances in this field and consider incorporation of glycocalyx biomarkers into research protocols and high-risk population screening.

Conclusion

The endothelial glycocalyx represents a novel frontier in the early detection and management of cardiovascular dysfunction. Biomarkers of glycocalyx degradation offer mechanistic, prognostic, and potentially therapeutic value, particularly in subclinical and high-risk patient populations. Integration of these biomarkers into clinical practice, guided by robust evidence and evolving guidelines, holds promise for improving cardiovascular outcomes through personalized and preventative strategies.